Wall Street Zen Upgrades Definitive Healthcare (NASDAQ:DH) to Buy

Definitive Healthcare (NASDAQ:DH) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Sunday.

DH has been the subject of a number of other research reports. Robert W. Baird set a $1.10 price target on Definitive Healthcare in a report on Friday, May 8th. Barclays cut their price objective on Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating for the company in a research report on Monday, March 30th. Zacks Research raised Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 28th. Bank of America reiterated an “underperform” rating and set a $0.70 target price on shares of Definitive Healthcare in a research report on Monday, June 29th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $2.47.

Definitive Healthcare Stock Down 0.4%

DH opened at $0.68 on Friday. Definitive Healthcare has a fifty-two week low of $0.62 and a fifty-two week high of $4.70. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.75 and a current ratio of 1.75. The company has a fifty day moving average of $0.81 and a two-hundred day moving average of $1.25. The stock has a market capitalization of $72.07 million, a price-to-earnings ratio of -0.42, a PEG ratio of 11.02 and a beta of 1.33.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. Definitive Healthcare had a negative net margin of 76.04% and a positive return on equity of 4.04%. The business had revenue of $55.93 million during the quarter, compared to the consensus estimate of $55.02 million. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. On average, research analysts expect that Definitive Healthcare will post 0.04 earnings per share for the current year.

Institutional Trading of Definitive Healthcare

Several large investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its position in shares of Definitive Healthcare by 564.2% during the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock worth $25,191,000 after purchasing an additional 7,404,363 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Definitive Healthcare by 1.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,073,197 shares of the company’s stock valued at $8,417,000 after purchasing an additional 33,612 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Definitive Healthcare by 11.7% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,216,007 shares of the company’s stock worth $4,937,000 after purchasing an additional 127,055 shares during the last quarter. Bank of America Corp DE boosted its stake in Definitive Healthcare by 23.7% during the 2nd quarter. Bank of America Corp DE now owns 769,397 shares of the company’s stock worth $3,001,000 after purchasing an additional 147,599 shares during the last quarter. Finally, Inspire Investing LLC boosted its stake in Definitive Healthcare by 505.7% during the 4th quarter. Inspire Investing LLC now owns 698,967 shares of the company’s stock worth $2,006,000 after purchasing an additional 583,562 shares during the last quarter. 98.67% of the stock is currently owned by hedge funds and other institutional investors.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.